latest educational series
Watch experts Drs. Raj Chovatiya and Matt Zirwas at an educational symposium on diagnostic considerations for atopic dermatitis and prurigo nodularis and how clinical signs and itch in these diseases are impacted by type 2 inflammation.
Grand Rounds: Atopic Dermatitis, the newest educational series from the Dermatology Digest® and the Journal of Dermatology for NPs and PAs®, offers peer-guided, case-based learning opportunities for challenging cases of this inflammatory skin disease.
This educational video series provides expert commentary on the results and implications of Level Up, the first head-to-head trial in atopic dermatitis assessing upadacitinib (Rinvoq, AbbVie) at a starting dose of 15mg daily vs. dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals) at its labeled dose.
Watch the MELA B3 Launch Live Broadcast and discover a groundbreaking new molecule, 18 years in the making, designed to address various forms of discoloration across the spectrum of skin tones.
This educational video series provides expert commentary on the current treatment landscape for patients with acne.


Adrianne Shapira Joins Crown’s Board of Directors
February 20, 2025

AD Pipeline Watch: U.S. FDA Clears IND for Zabalafin Hydrogel in AD
February 19, 2025

Tampere University, Theravia Partner to Advance New EB Drug
February 19, 2025


Galderma’s Nemolizumab Approved for AD and PN in the UK and Switzerland
February 18, 2025
Past Conference Coverage
Educational Series
Podcast Series